Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Operating Leases (2019 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Operating Leases for 7 consecutive years, with $405000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 50.67% to $405000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $405000.0, a 50.67% decrease, with the full-year FY2024 number at $709000.0, down 36.01% from a year prior.
  • Operating Leases was $405000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $522000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.9 million in Q1 2022 to a low of $1000.0 in Q3 2021.
  • A 5-year average of $926052.6 and a median of $932000.0 in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 99.49% in 2021, then surged 171200.0% in 2022.
  • NovaBay Pharmaceuticals' Operating Leases stood at $246000.0 in 2021, then soared by 545.53% to $1.6 million in 2022, then plummeted by 30.23% to $1.1 million in 2023, then tumbled by 36.01% to $709000.0 in 2024, then tumbled by 42.88% to $405000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Operating Leases are $405000.0 (Q3 2025), $522000.0 (Q2 2025), and $638000.0 (Q1 2025).